Hostname: page-component-cd9895bd7-q99xh Total loading time: 0 Render date: 2024-12-25T06:57:46.309Z Has data issue: false hasContentIssue false
  • English
  • Français

Letters to the Editor

Published online by Cambridge University Press:  06 January 2021

Thomas G. Slama
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Letters to the Editor
Information
American Journal of Law & Medicine , Volume 38 , Issue 4 , December 2012 , pp. 742 - 744
Copyright
Copyright © American Society of Law, Medicine and Ethics and Boston University 2012

References

1 Ferguson, Johanna, Note, Cure Unwanted? Exploring the Chronic Lyme Disease Controversy and Why Conflicts of Interest in Practice Guidelines May Be Guiding Us Down the Wrong Path, 38 AM. J.L. & MED. 196 (2012).Google ScholarPubMed

2 See, e.g., Dattwyler, Raymond J. et al., A Comparison of Two Treatment Regimens of Ceftriaxone in Late Lyme Disease, 117 WIENER KLINISCHE WOCHENSCHRIFT 393 (2005) (Austria)CrossRefGoogle ScholarPubMed; Fallon, B.A. et al., A Randomized Placebo-Controlled Trial of Repeated IV Antibiotic Therapy for Lyme Encephalopathy, 70 NEUROLOGY 992 (2008)CrossRefGoogle ScholarPubMed; Feder, H. Jr., et al., A Critical Appraisal of “Chronic Lyme Disease,” 357 NEW ENG. J. MED. 1422 (2007)CrossRefGoogle Scholar; Klempner, Mark S. et al., Two Controlled Trials of Antibiotic Treatment in Patients with Persistent Symptoms and a History of Lyme Disease, 345 NEW ENG. J. MED. 85 (2001)CrossRefGoogle Scholar; Krupp, L.B. et al., Study and Treatment of Post Lyme Disease (STOP-LD): A Randomized Double Masked Clinical Trial, 60 NEUROLOGY 1923 (2003)CrossRefGoogle ScholarPubMed; Oksi, J. et al., Duration of Antibiotic Treatment in Disseminated Lyme Borreliosis: A Double-Blind, Randomized, Placebo-Controlled, Multi-Center Clinical Study, 26 EUR. J. CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES 571 (2007)CrossRefGoogle Scholar; Wormser, Gary P. et al., The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America, 43 CLINICAL INFECTIOUS DISEASES 1089 (2006) [hereinafter, Wormser et al., The Clinical Assessment]CrossRefGoogle ScholarPubMed; Wormser, Gary P. et al., Duration of Antibiotic Therapy for Early Lyme Disease: A Randomized, Double-Blind, Placebo-Controlled Trial, 138 ANNALS INTERNAL MED. 697 (2003).CrossRefGoogle ScholarPubMed

3 See Ettestad, Paul J. et al., Biliary Complications in the Treatment of Unsubstantiated Lyme Disease, 171 J. INFECTIOUS DISEASES 356, 359 (1995)CrossRefGoogle ScholarPubMed; Krupp et al., supra note 2, at 1923; Patel, Robin et al., Death from Inappropriate Therapy for Lyme Disease, 31 CLINICAL INFECTIOUS DISEASES 1107, 1108 (2000).CrossRefGoogle ScholarPubMed

4 Press Release, Conn. Att’y Gen.'s Office, A General's Investigation Reveals Flawed Lyme Disease Guideline Process, IDSA Agrees to Reassess Guidelines, Install Independent Arbiter (May 1, 2008), available at http://www.ct.gov/ag/cwp/view.asp?a=2795&q=414284.

5 Johnson, L. & Stricker, R.B., Attorney General Forces Infectious Disease Society of America to Redo Lyme Guidelines Due to Flawed Development Process, 35 J. MED. ETHICS 283 (2009).CrossRefGoogle ScholarPubMed

6 Auwaerter, Paul G. et al., Scientific Evidence and Best Patient Care Practices Should Guide the Ethics of Lyme Disease Activism, 37 J. MED. ETHICS 68, 71 (2011).CrossRefGoogle ScholarPubMed

7 See id.; see also Auwaerter, Paul G. et al., Antiscience and Ethical Concerns Associated with Advocacy of Lyme Disease, 11 LANCET INFECTIOUS DISEASES 713, 715 (2011)CrossRefGoogle ScholarPubMed; David Whelan, Ticks Aren't the Only Parasites Living Off Patients in Borreliosis-Prone Areas, FORBES (Mar. 12, 2007), http://www.forbes.com/forbes/2007/0312/096.html.

8 Ferguson, supra note 1, at 198.

9 See Wormser et al., The Clinical Assessment, supra note 2, at 1121.

10 See Ferguson, supra note 1, at 215-16.

11 Lantos, Paul M. et al., Final Report of the Lyme Disease Review Panel of the Infectious Diseases Society of America, 51 CLINICAL INFECTIOUS DISEASES 1 (2010).CrossRefGoogle ScholarPubMed

12 Ferguson, supra note 1, at 216.

13 See Lantos et al., supra note 11, at 1.

14 See Ferguson, supra note 1, at 216.

15 Lantos et al., supra note 11, at 5.

16 Ferguson, supra note 1, at 216.

17 See Feder, Jr. et al., supra note 2, at 1427; Auwaerter et al., supra note 6, at 69-70.

18 See supra note 2 and accompanying text.

19 See Patel et al., supra note 3, at 1108-09; see also Holzbauer, Stacy M. et al., Death Due to Community-Associated Clostridium Difficile in a Woman Receiving Prolonged Antibiotic Therapy for Suspected Lyme Disease, 51 CLINICAL INFECTIOUS DISEASES 369 (2010)CrossRefGoogle Scholar; Steve Fry, Former Doctor John Toth Faces Federal Case, CJONLINE.COM (Dec. 6, 2008), http://cjonline.com/stories/120608/loc_364328990.shtml.

20 Patricia Callahan, A Lyme Disease Diagnosis Gone Wrong, L.A. TIMES, Dec. 27, 2010, http://articles.latimes.com/2010/dec/27/health/la-he-lyme-disease-side2-20101227.